- Home
- ROIV vs APPF Comparison
ROIV vs APPF Comparison
Compare ROIV & APPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- APPF
- Stock Information
- Founded
- ROIV 2014
- APPF 2006
- Country
- ROIV United Kingdom
- APPF United States
- Employees
- ROIV N/A
- APPF N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- APPF Computer Software: Prepackaged Software
- Sector
- ROIV Health Care
- APPF Technology
- Exchange
- ROIV Nasdaq
- APPF Nasdaq
- Market Cap
- ROIV 8.6B
- APPF 10.0B
- IPO Year
- ROIV N/A
- APPF 2015
- Fundamental
- Price
- ROIV $15.28
- APPF $276.75
- Analyst Decision
- ROIV Strong Buy
- APPF Buy
- Analyst Count
- ROIV 4
- APPF 6
- Target Price
- ROIV $15.50
- APPF $309.83
- AVG Volume (30 Days)
- ROIV 7.8M
- APPF 229.9K
- Earning Date
- ROIV 11-11-2025
- APPF 10-23-2025
- Dividend Yield
- ROIV N/A
- APPF N/A
- EPS Growth
- ROIV N/A
- APPF 64.56
- EPS
- ROIV N/A
- APPF 5.55
- Revenue
- ROIV $23,233,000.00
- APPF $862,674,000.00
- Revenue This Year
- ROIV N/A
- APPF $21.09
- Revenue Next Year
- ROIV $281.14
- APPF $17.60
- P/E Ratio
- ROIV N/A
- APPF $49.54
- Revenue Growth
- ROIV N/A
- APPF 19.47
- 52 Week Low
- ROIV $8.73
- APPF $189.01
- 52 Week High
- ROIV $16.05
- APPF $326.04
- Technical
- Relative Strength Index (RSI)
- ROIV 82.00
- APPF 50.90
- Support Level
- ROIV $13.81
- APPF $275.65
- Resistance Level
- ROIV $14.48
- APPF $284.48
- Average True Range (ATR)
- ROIV 0.47
- APPF 5.94
- MACD
- ROIV 0.22
- APPF -0.78
- Stochastic Oscillator
- ROIV 81.67
- APPF 33.84
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About APPF AppFolio Inc.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.